Cancer
Malignant Central Nervous System Neoplasm
CI-CAN-00001115Explore in graph →
Top-level823 active trials5 approved drugs103 evidence items
Loading cancer entity…
Loading cancer entity…
Cancer
CI-CAN-00001115Explore in graph →
Clinical trials
2,866 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (418)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT00509821 | Enzastaurin Before and Concomitant With Radiation, Followed by Enzastaurin in Participants With Newly Diagnosed Glioblastoma | completed | Phase 2 | 60 | Eli Lilly and CompanyINDUSTRY | 1 | Apr 5, 2019 | clinicaltrials |
| NCT02395692 | Methoxyamine and Temozolomide in Treating Patients With Recurrent Glioblastoma | terminated | Phase 2 | 20 | National Cancer Institute (NCI)NIH | 1 | Apr 4, 2019 | clinicaltrials |
| NCT00441142 | Zactima With Temodar During Radiation Treatment for Newly Diagnosed Stage IV Brain Tumors(Zactima) | completed | Phase 1 / Phase 2 | 119 | Patrick Y. Wen, MDOTHER | 1 | Mar 5, 2019 | clinicaltrials |
| NCT01186406 | Gliadel, XRT, Temodar, Avastin Followed by Avastin, Temodar for Newly Diagnosed Glioblastoma Multiforme (GBM) | terminated | Phase 2 | 41 | Duke UniversityOTHER | 1 | Feb 15, 2019 | clinicaltrials |
| NCT01044966 | A Study of Intraventricular Liposomal Encapsulated Ara-C (DepoCyt) in Patients With Recurrent Glioblastoma | terminated | Phase 1 / Phase 2 | 12 | Medical University of South CarolinaOTHER | 1 | Feb 12, 2019 | clinicaltrials |
| NCT00863460 | Cranial Radiotherapy or Intensive Chemotherapy With Hematopoietic Stem Cell Rescue for Primary Central Nervous System Lymphoma in Young Patients(PRECIS) | unknown | Phase 2 | 140 | Institut CurieOTHER | 1 | Feb 5, 2019 | clinicaltrials |
| NCT02796729 | CEST- Glucose Enhanced MRI for Metastatic Brain Tumours | terminated | Phase 2 | 3 | British Columbia Cancer AgencyOTHER | 1 | Jan 28, 2019 | clinicaltrials |
| NCT01562197 | A Randomized Phase II Clinical Trial on the Efficacy of Axitinib as a Monotherapy or in Combination With Lomustine for the Treatment of Patients With Recurrent Glioblastoma(AxiGII) | completed | Phase 2 | 56 | Bart NeynsOTHER | 1 | Jan 24, 2019 | clinicaltrials |
| NCT03291314 | Clinical Trial on the Combination of Avelumab and Axitinib for the Treatment of Patients With Recurrent Glioblastoma(GliAvAx) | completed | Phase 2 | 52 | Universitair Ziekenhuis BrusselOTHER | 1 | Jan 23, 2019 | clinicaltrials |
| NCT01846871 | Tivozanib for Recurrent Glioblastoma | completed | Phase 2 | 10 | Massachusetts General HospitalOTHER | 1 | Jan 8, 2019 | clinicaltrials |
| NCT01614795 | Cixutumumab and Temsirolimus in Treating Younger Patients With Recurrent or Refractory Sarcoma | completed | Phase 2 | 46 | National Cancer Institute (NCI)NIH | 2 | Dec 11, 2018 | clinicaltrials |
| NCT01293539 | Intra-arterial Chemotherapy for the Treatment of Intraocular Retinoblastoma | terminated | Phase 2 | 10 | Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsOTHER | 1 | Nov 27, 2018 | clinicaltrials |
| NCT03746288 | To Evaluate the Efficacy and Safety of CAN008 Combined With Re-irradiation (rRT) for Treating Patients With Recurrent Glioblastoma (GBM) | unknown | Phase 2 | 60 | CANbridge Life Sciences Ltd.INDUSTRY | 0 | Nov 19, 2018 | clinicaltrials |
| NCT03120000 | PQR309 in Phase 2 in Patients With Relapsed or Refractory Primary Central Nervous System Lymphoma | withdrawn | Phase 2 | 0 | PIQUR Therapeutics AGINDUSTRY | 1 | Nov 16, 2018 | clinicaltrials |
| NCT03733327 | BUCYE Conditioning Regimen for PCNSL Undergoing Auto-HSCT | unknown | Phase 2 / Phase 3 | 20 | Nanfang Hospital, Southern Medical UniversityOTHER | 1 | Nov 7, 2018 | clinicaltrials |
| NCT00038493 | Temozolomide and SCH66336 for Recurrent Glioblastoma Multiforme | completed | Phase 2 | 23 | M.D. Anderson Cancer CenterOTHER | 1 | Oct 29, 2018 | clinicaltrials |
| NCT01977677 | Plerixafor After Radiation Therapy and Temozolomide in Treating Patients With Newly Diagnosed High Grade Glioma | completed | Phase 1 / Phase 2 | 30 | Lawrence RechtOTHER | 1 | Oct 23, 2018 | clinicaltrials |
| NCT02850744 | Study to Evaluate the Efficacy, Safety, Pharmacokinetics and Pharmacodynamic Effects of PQR309 in Glioblastoma Patients | terminated | Phase 2 | 10 | PIQUR Therapeutics AGINDUSTRY | 1 | Oct 19, 2018 | clinicaltrials |
| NCT00329719 | Sorafenib Tosylate and Temsirolimus in Treating Patients With Recurrent Glioblastoma | completed | Phase 1 / Phase 2 | 115 | National Cancer Institute (NCI)NIH | 1 | Oct 16, 2018 | clinicaltrials |
| NCT02253212 | Safety of BBB Opening With the SonoCloud(SONOCLOUD) | completed | Phase 1 / Phase 2 | 27 | Assistance Publique - Hôpitaux de ParisOTHER | 1 | Oct 12, 2018 | clinicaltrials |
| NCT00323115 | Phase II Feasibility Study of Dendritic Cell Vaccination for Newly Diagnosed Glioblastoma Multiforme | completed | Phase 2 | 11 | Dartmouth-Hitchcock Medical CenterOTHER | 1 | Oct 10, 2018 | clinicaltrials |
| NCT00433381 | Bevacizumab and Irinotecan or Temozolomide in Treating Patients With Recurrent or Refractory Glioblastoma Multiforme or Gliosarcoma | completed | Phase 2 | 123 | National Cancer Institute (NCI)NIH | 1 | Sep 17, 2018 | clinicaltrials |
| NCT03212807 | Study Of Durvalumab and Lenalidomide In R/R EBV Associated DLBCL Subtypes, Primary CNS And Testicular DLBCL(DuRIANS) | withdrawn | Phase 2 | 0 | Singapore General HospitalOTHER | 1 | Sep 13, 2018 | clinicaltrials |
| NCT01868906 | FMISO-PET in Brain Tumors and SCS Effect(FMISOPETSCS) | terminated | Phase 2 | 6 | Bernardino Clavo, MD, PhDOTHER | 1 | Aug 24, 2018 | clinicaltrials |
| NCT01112527 | PF-00299804 in Adult Patients With Relapsed/Recurrent Glioblastoma | completed | Phase 2 | 58 | Massachusetts General HospitalOTHER | 1 | Aug 16, 2018 | clinicaltrials |
| NCT00679354 | Cilengitide in Treating Younger Patients With Recurrent or Progressive High-Grade Glioma That Has Not Responded to Standard Therapy | completed | Phase 2 | 30 | National Cancer Institute (NCI)NIH | 2 | Aug 1, 2018 | clinicaltrials |
| NCT01266031 | Phase I/II Adaptive Randomized Trial of Bevacizumab Versus Bevacizumab Plus Vorinostat in Adults With Recurrent Glioblastoma | completed | Phase 1 / Phase 2 | 96 | National Cancer Institute (NCI)NIH | 1 | Jul 31, 2018 | clinicaltrials |
| NCT01575275 | Aminolevulinic Acid in Visualizing a Tumor During Surgery in Patients With Glioblastoma Multiforme | terminated | Phase 2 | 8 | Michael Vogelbaum, MD, PhDOTHER | 1 | Jul 31, 2018 | clinicaltrials |
| NCT02698280 | Bevacizumab and Nimustine in Patients With Recurrent High Grade Glioma | completed | Phase 2 | 23 | Huashan HospitalOTHER | 1 | Jul 31, 2018 | clinicaltrials |
| NCT03607643 | A Study of the Efficacy of Cannabidiol in Patients With Multiple Myeloma, Glioblastoma Multiforme, and GI Malignancies | unknown | Phase 1 / Phase 2 | 160 | Leaf Vertical Inc.INDUSTRY | 1 | Jul 31, 2018 | clinicaltrials |
| NCT01789255 | Vorinostat, Tacrolimus, and Methotrexate in Preventing GVHD After Stem Cell Transplant in Patients With Hematological Malignancies | completed | Phase 2 | 12 | National Cancer Institute (NCI)NIH | 1 | Jul 24, 2018 | clinicaltrials |
| NCT02478164 | Trial of Ponatinib in Patients With Bevacizumab-Refractory Glioblastoma | completed | Phase 2 | 17 | Dana-Farber Cancer InstituteOTHER | 1 | Jul 24, 2018 | clinicaltrials |
| NCT02233049 | Biological Medicine for Diffuse Intrinsic Pontine Glioma (DIPG) Eradication(BIOMEDE) | unknown | Phase 2 | 250 | Gustave Roussy, Cancer Campus, Grand ParisOTHER | 1 | Jul 23, 2018 | clinicaltrials |
| NCT00749723 | Therapy Optimization Trial for the Treatment of Relapsed or Refractory Brain Tumors in Children(HIT-REZ-2005) | completed | Phase 2 / Phase 3 | 174 | University Hospital, BonnOTHER | 1 | Jul 20, 2018 | clinicaltrials |
| NCT01836549 | Imetelstat Sodium in Treating Younger Patients With Recurrent or Refractory Brain Tumors | terminated | Phase 2 | 43 | Pediatric Brain Tumor ConsortiumNETWORK | 1 | Jul 20, 2018 | clinicaltrials |
| NCT00107003 | GW572016 to Treat Recurrent Malignant Brain Tumors | completed | Phase 2 | 9 | National Cancer Institute (NCI)NIH | 1 | Jul 5, 2018 | clinicaltrials |
| NCT01857453 | Interest of a Dose Decrease for Radiotherapy Associated With Chemotherapy for Treatment of Standard Risk Adult Medulloblastomas(RSMA2010) | unknown | Phase 2 | 97 | Central Hospital, Nancy, FranceOTHER | 1 | Jul 5, 2018 | clinicaltrials |
| NCT00335764 | Sorafenib Combined With Erlotinib, Tipifarnib, or Temsirolimus in Treating Patients With Recurrent Glioblastoma Multiforme or Gliosarcoma | completed | Phase 1 / Phase 2 | 92 | National Cancer Institute (NCI)NIH | 1 | Jul 2, 2018 | clinicaltrials |
| NCT01648348 | Bevacizumab With or Without Anti-Endoglin Monoclonal Antibody TRC105 in Treating Patients With Recurrent Glioblastoma Multiforme | completed | Phase 1 / Phase 2 | 116 | National Cancer Institute (NCI)NIH | 1 | May 23, 2018 | clinicaltrials |
| NCT02157103 | A Study of Subcutaneous Bevacizumab in Relapsed / Progressive Glioblastoma | completed | Phase 2 | 3 | Emory UniversityOTHER | 1 | May 17, 2018 | clinicaltrials |
| NCT02332889 | Phase I/II: Decitabine/Vaccine Therapy in Relapsed/Refractory Pediatric High Grade Gliomas/Medulloblastomas/CNS PNETs | terminated | Phase 1 / Phase 2 | 1 | University of LouisvilleOTHER | 1 | May 4, 2018 | clinicaltrials |
| NCT01602588 | A Randomised Trial Investigating the Additional Benefit of Hydroxychloroquine(HCQ)to Short Course Radiotherapy (SCRT) in Patients Aged 70 Years and Older With High Grade Gliomas (HGG)(HCQ) | completed | Phase 2 | 54 | University College, LondonOTHER | 1 | May 3, 2018 | clinicaltrials |
| NCT01860638 | A Comparison of Continuous Bevacizumab (Avastin) Treatment or Placebo in Addition to Lomustine Followed by Standard of Care After Disease Progression in Participants With Glioblastoma | completed | Phase 2 | 296 | Hoffmann-La RocheINDUSTRY | 15 | Apr 30, 2018 | clinicaltrials |
| NCT02227576 | Prevention of Thrombocytopenia in Glioblastoma Patients(PLATUM) | terminated | Phase 2 | 20 | University Hospital, LilleOTHER | 1 | Apr 25, 2018 | clinicaltrials |
| NCT02945826 | uPAR-PET/MRI in Glioblastoma Multiforme | unknown | Phase 2 | 35 | Rigshospitalet, DenmarkOTHER | 1 | Apr 10, 2018 | clinicaltrials |
| NCT00003456 | Antineoplaston Therapy in Treating Patients With Newly-diagnosed Glioblastoma Multiforme | completed | Phase 2 | 40 | Burzynski Research InstituteOTHER | 1 | Mar 22, 2018 | clinicaltrials |
| NCT00003474 | Antineoplaston Therapy in Treating Adults With Residual/Recurrent/Progressive Glioblastoma Multiforme | completed | Phase 2 | 40 | Burzynski Research InstituteOTHER | 1 | Mar 22, 2018 | clinicaltrials |
| NCT02654041 | Study of Induction of Hypothyroxinemia Adjunct to Conventional Therapies in GBM Patients | terminated | Phase 2 | 3 | Musli Thyropeutics Ltd.INDUSTRY | 1 | Mar 22, 2018 | clinicaltrials |
| NCT00200161 | Temozolomide & RT Followed by Dose Dense vs Temozolomide & Retinoic Acid in Pts w/Glioblastoma | completed | Phase 2 | 127 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Mar 7, 2018 | clinicaltrials |
| NCT00305864 | Motexafin Gadolinium, Temozolomide, and Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma Multiforme or Gliosarcoma | completed | Phase 1 / Phase 2 | 118 | National Cancer Institute (NCI)NIH | 1 | Mar 5, 2018 | clinicaltrials |
Data updated 24 days agoSource updated Apr 5, 2019source: clinicaltrials